About this episode
Intellia Therapeutics公司和再生元（Regeneron）公司联合宣布了一款基于CRISPR/Cas9技术的基因编辑疗法在临床试验中获得的积极结果，这是首个支持体内CRISPR基因编辑安全性和效果的临床数据。这项研究的结果同时在《新英格兰医学杂志》上发表。
Get every episode summarized
Each time 天方烨谈 publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
